Janet Dillione - 18 Sep 2026 Form 4 Insider Report for CorMedix Inc. (CRMD)

Reporting relationship: Director
Issuer ticker: CRMD
Reported as of: 18 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Sep 2026, 21:36:46 UTC
Prior SEC filing: 27 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Beth Zelnick Kaufman, attorney-in-fact

Key filing fact

Janet Dillione filed Form 4 for CorMedix Inc. (CRMD) on 18 Sep 2026.

Key facts

This page summarizes Janet Dillione's Form 4 filing for CorMedix Inc. (CRMD).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 Sep 2026, 21:36.

Change

Previous filing in this sequence was filed on 27 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001489798 Primary reporting owner

Dillione Janet

Relationship: Director
Address: C/O CORMEDIX INC.,, 389 INTERPACE PKWY, SUITE 450, PARSIPPANY
Signature: /s/ Beth Zelnick Kaufman, attorney-in-fact
Signature date: 18 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRMD transaction

Common Stock

Options Exercise

Transaction value
Shares: +48,909
Change %: +71%
Price
Shares after: 117,835
Date: 18 Sep 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRMD transaction Derivative

Phantom Stock

Options Exercise

Transaction value
Shares: -48,909
Change %: -100%
Price
Shares after: 0
Date: 18 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 48,909
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each phantom stock unit is the economic equivalent of one share of common stock. On September 17, 2025, the Company terminated the CorMedix Inc. Deferred Compensation Plan for Directors (the "Plan"). On September 18, 2026, in connection with the termination of the Plan, all of the Reporting Person's phantom stock units were settled in an equal number of shares of common stock.